Related News

Combination Oladaterol and Tiotropium enters Phase III for COPD Respiratory Page

Boehringer Ingelheim has initiated its Phase III trial that will investigate Spiriva (tiotropium) in combination with a new compound, olodaterol, a novel once-daily long-acting beta-2 agonist ,for the treatment of chronic obstructive pulmonary disease. Spiriva (tiotropium), a long-acting muscarinic antagonist (LAMA) co-marketed with Pfizer, is the most prescribed COPD drug worldwide, while olodaterol is a novel once-daily long-acting beta-2 agonist (LABA) which Boehringer says has been developed as "an ideal partner" to its big-selling drug. The German company said it is putting the combo into late-stage studies on the back on promising olodaterol Phase III results, which will be published in the near future.

GLOW 1 and GLOW 3 studies to support SeebriBreezhaler application. Respiratory Page

The GLOW 1 and GLOW 3 studies show that investigational NVA237 (glycopyrronium bromide)from Novartis significantly increased patients' lung function compared to placebo with a fast onset of action at first dose, as well as improving exercise endurance. NVA237 is a new drug in the long-acting anti-muscarinic (LAMA) class which has recently been submitted for approval in the European Union under the brand-name Seebri Breezhaler. Novartis plan to file the drug as monotherapy and in combination with indacaterol (Onbrez BreezHaler ).

Daxas shows positive data on "Frequent exacerbations" in COPD Respiratory Page

New findings from a post-hoc pooled analysis of two one-year studies of more than 1,500 roflumilast-treated patients with severe COPD, chronic bronchitis and a history of exacerbations show that Daxas (roflumilast) from Nycomed ,helps to prevent exacerbations in COPD patients of the 'frequent exacerbator' phenotype. The 'frequent exacerbator' group show worse health status and faster disease progression than those who are 'infrequent exacerbators'.The data, presented at the 2011 European Respiratory Society (ERS) Annual Congress in Amsterdam, 24 - 28 September, have important implications for the management of COPD in this patient population, who are at increased risk of disease progression compared with those who have no or infrequent exacerbations. Frequent exacerbations are of concern to a significant group of COPD patients, despite access to available therapy. They are distressing for patients and lead to poorer health status and faster disease progression, imposing a substantial burden on patients. Exacerbations also significantly impact the functional ability of COPD patients - patients with frequent exacerbations reduce the time they spend outdoors at a faster rate compared with those with infrequent exacerbations and are more likely to become housebound. Lead investigator was was Professor Jadwiga Wedzicha see Wedzicha JA et al. Efficacy of roflumilast in the frequent exacerbation COPD phenotype. Presented at 2011 European Respiratory Society Annual Meeting, Poster Discussion : Biomarkers and exacerbations of asthma and COPD, Tuesday 28 September 2011, 8:30-10:30, P3355

More News